<DOC>
	<DOC>NCT01336582</DOC>
	<brief_summary>Primary Objective: Evaluation of the pharmacokinetic equivalence of two Docetaxel formulations in terms of AUC and Cmax.</brief_summary>
	<brief_title>Pharmacokinetic Study of SYP-0704A and Taxotere to Treat Patient With Advanced Solid Cancer</brief_title>
	<detailed_description>Comparison of pharmacokinetic parameters (T1/2β, CL, Vdss) Safety as measured by adverse events</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Subjects who aged 18 years or older. Subjects whose written informed consent was obtained complying with the local regulatory requirements prior to their participation in the trial. Subjects who have histologically or cytologically confirmed advanced solid tumor. Subjects who are a suitable candidate for single agent docetaxel therapy for their advanced solid tumors that have failed to standard therapy. Subjects who have fully recovered from reversible toxic effects of prior therapy. The prior chemotherapy, immunotherapy, hormone therapy, surgery, and/or radiotherapy should be completed at least 21 days before the first administration of investigational product. Subjects who have had a major surgery other than tumor ablation within 2 weeks prior to the screening/baseline visit. Subjects who have a history of metastasis or currently have a metastasis to the central nervous system (CNS). Subjects who have a preexisting sensory or motor neuropathy of grade ≥ 2 based on NCI CTCAE V3.0.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>suitable candidate</keyword>
	<keyword>single agent docetaxel therapy</keyword>
	<keyword>Advanced Solid Tumor</keyword>
</DOC>